{"id":"dihydroartemisinin-piperaquin","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dihydroartemisinin (DHA), the active metabolite of artemisinin, generates reactive oxygen species that damage parasite proteins and DNA. Piperaquine is a quinoline-based antimalarial that inhibits heme polymerization, causing toxic heme accumulation in the parasite. Together, this combination provides rapid parasite clearance and extended post-treatment suppression.","oneSentence":"Dihydroartemisinin piperaquine is a fixed-dose combination antimalarial that kills malaria parasites through artemisinin-induced oxidative stress and piperaquine-mediated heme polymerization inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:30.107Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax"}]},"trialDetails":[{"nctId":"NCT04147546","phase":"PHASE3","title":"Additional Screening With Sensitives RDTs and Malaria","status":"COMPLETED","sponsor":"Institut de Recherche en Sciences de la Sante, Burkina Faso","startDate":"2020-08-31","conditions":"Plasmodium Falciparum Malaria, Malaria Diagnosis","enrollment":340},{"nctId":"NCT04149106","phase":"PHASE3","title":"Seasonal Malaria Chemoprevention With Dihydroartemisin Piperaquin vs. Sulfadoxine-pyrimethamin+Amodiaquin","status":"UNKNOWN","sponsor":"University Clinical Research Center, Mali","startDate":"2019-07-01","conditions":"Malaria,Falciparum","enrollment":4556},{"nctId":"NCT04778813","phase":"PHASE4","title":"Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in Burkina Faso (CHIMIO2)","status":"UNKNOWN","sponsor":"Centre national de recherche et de formation sur le paludisme","startDate":"2021-06-01","conditions":"Malaria, Burkina Faso","enrollment":1050}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["DHAPQ"],"phase":"phase_3","status":"active","brandName":"Dihydroartemisinin piperaquin","genericName":"Dihydroartemisinin piperaquin","companyName":"University Clinical Research Center, Mali","companyId":"university-clinical-research-center-mali","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dihydroartemisinin piperaquine is a fixed-dose combination antimalarial that kills malaria parasites through artemisinin-induced oxidative stress and piperaquine-mediated heme polymerization inhibition. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}